Yes, SS-31, or elamipretide, now branded as Forzinity, recently received FDA accelerated approval as the first treatment for Barth syndrome.

Yes, SS-31 has undergone extensive human testing, including the pivotal trial that led to FDA approval. Studies showed improvements in muscle strength, endurance, and mitochondrial function in patients with Barth syndrome and related disorders.

SS-31 targets and protects mitochondria, the cell’s energy source, helping improve how cells produce and use energy. In clinical trials, it improved muscle performance and showed potential benefits for heart, muscle, and metabolic health. Working with a licensed provider helps ensure proper monitoring and product quality.

Yes, human studies show SS-31 is well tolerated, with the most common side effects being mild injection-site reactions such as redness or irritation. The FDA continues to monitor long-term safety through post-approval studies.

Forzinity is approved specifically for Barth syndrome patients weighing at least 30 kg. Anyone outside that group, or individuals who are pregnant, nursing, or managing complex metabolic conditions, should use it under medical supervision.

SS-31 is administered as a once-daily subcutaneous injection, allowing consistent delivery to mitochondria-rich tissues such as muscle and heart.

Yes, SS-31 is often paired with other longevity and performance peptides, as well as energy-support therapies like NAD+. These combinations target different parts of the cellular-energy pathway, creating a more comprehensive approach to recovery, vitality, and healthy aging. Any stack should be clinician-supervised.